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A B S T R A C T
Activated endothelial cells play a pivotal role in the pathology of inﬂammatory disorders and thus present a
target for therapeutic intervention by drugs that intervene in inﬂammatory signaling cascades, such as rapa-
mycin (mammalian target of rapamycin (mTOR) inhibitor). In this study we developed anti-E-selectin im-
munoliposomes for targeted delivery to E-selectin over-expressing tumor necrosis factor-α (TNF-α) activated
endothelial cells. Liposomes composed of 1,2-dipalmitoyl-sn-glycero-3.;hosphocholine (DPPC), Cholesterol, and
1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000]-maleimide (DSPE-
PEG-Mal) were loaded with rapamycin via lipid ﬁlm hydration, after which they were further functionalized by
coupling N-succinimidyl-S-acetylthioacetate (SATA)-modiﬁed mouse anti human E-selectin antibodies to the
distal ends of the maleimidyl (Mal)-PEG groups. In cell binding assays, these immunoliposomes bound speciﬁ-
cally to TNF-α activated endothelial cells. Upon internalization, rapamycin loaded immunoliposomes inhibited
proliferation and migration of endothelial cells, as well as expression of inﬂammatory mediators. Our ﬁndings
demonstrate that rapamycin-loaded immunoliposomes can speciﬁcally inhibit inﬂammatory responses in in-
ﬂamed endothelial cells.
1. Introduction
The mammalian target of the drug rapamycin is a 289-kDa serine/
threonine kinase, typically known as mammalian target of rapamycin
(mTOR). This mTOR kinase is a component of two diﬀerent cellular
signaling regulating complexes, known as mTOR complex 1 and 2
(mTORc1 and mTORc2) (Kim et al., 2002; Jacinto et al., 2004;
Sarbassov et al., 2004; Wullschleger et al., 2006). The aforementioned
proteins interact with speciﬁc downstream targets that are responsible
for the interconnection of mTOR to diﬀerent downstream signaling
pathways such as Akt, SGK1 and 4E-BP1 that are involved in a variety
of cellular processes such as cell survival, proliferation and cytoskeletal
organization. Recent studies have highlighted the pivotal role of the
mTOR pathways in inﬂammatory disorders (Cejka et al., 2010; Xie
et al., 2014; Weichhart et al., 2015; Li et al., 2016). Also, a signiﬁcant
eﬀect of mTOR on the progression of chronic kidney disease (CKD) has
recently been suggested in several preclinical studies (Lieberthal and
Levine, 2009, 2012). Other preclinical studies using animal models (e.g.
rat models of CKD) have shown that the inhibition of mTOR signaling
pathways by rapamycin resulted in a signiﬁcant reduction of the inﬂux
of inﬂammatory cell into the diseased area (Bonegio et al., 2005; Wu
et al., 2006). The inhibition of mTOR signaling pathways by rapamycin
was also shown to signiﬁcantly reduce the release of pro-inﬂammatory
and pro-ﬁbrotic cytokines, as well as ﬁbrotic tissue formation, thus
improving overall kidney function (Bonegio et al., 2005; Wu et al.,
2006).
Rapamycin is a macrolide compound with hydrophobic character-
istics (Log P: 4.3) (Simamora and Yalkowsky, 2001) resulting in poor
water solubility, slow dissolution rate and consequential low oral
bioavailability (Simamora and Yalkowsky, 2001; Hu et al., 2012). Na-
nocarrier formulations can overcome the problems associated with the
poor biopharmaceutical characteristics of rapamycin, and thus can
contribute to an improved safety and eﬃcacy proﬁle (Woo et al., 2012;
Chen et al., 2013; Shah et al., 2013). Several rapamycin formulations
have been reported in literature, based on various types of nanocarrier
systems such as polymeric blend nanoparticles composed of the diblock
copolymer polyethylene glycol–poly-L-lactic acid (mPEG–PLA) mixed
with acid-terminated PLA (Woo et al., 2012); micelles composed of
mixed diblock copolymers mPEG-b-P(HPMA-Lac-co-His) and mPEG-b-
PLA (Chen et al., 2013); and liposomes composed of soy
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phosphatidylcholine (SPC), cholesterol (Chol) and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[amino(polyethyleneglycol)-2000]
(DSPE-PEG) (Eloy JO, 2016).
While many of the current anti-inﬂammatory therapeutic ap-
proaches are focused on attempts to suppress the activity of immune
eﬀector cells, recently there has been a growing interest toward un-
derstanding the role of endothelial cells in leukocyte recruitment into
inﬂamed tissues (Panés et al., 1999; Muller, 2003). Endothelial cells are
in direct contact with the blood which makes these cells attractive
targets for nanocarrier delivery strategies. Selective delivery to in-
ﬂamed endothelial cells is possible by targeting adhesion molecules
(e.g. E-selectin, P-selectin, intercellular adhesion molecule (ICAM) and
vascular cell adhesion molecule-1 (VCAM-1)) on their surface. Adhe-
sion molecules are selectively (over)expressed in the presence of in-
ﬂammatory stimulants such as interleukin-1 (IL-1), lipopolysaccharides
(LPS) and tumor necrosis factor-α (TNF-α) (Cook-Mills and Deem,
2005). Proper cell selective delivery of potent anti-inﬂammatory agents
may provide an important tool to both increase the eﬃcacy and reduce
the side eﬀects of such therapeutic compound (i.e. rapamycin) in the
treatment of inﬂammatory disorders (Koning et al., 2006).
In this study, we have developed anti-E-selectin antibody (Ab)
coupled immunoliposomes, loaded with rapamycin, for targeted de-
livery to TNF-α activated endothelial cells (Fig. 1). This work discusses
the characterization and formulation of the immunoliposomes, while
their cell binding and uptake properties by TNF-α activated endothelial
cells are also investigated. To evaluate the pharmacologic eﬀects of the
rapamycin containing immunoliposomes, cell proliferation and moti-
lity, phosphorylation of mTOR kinases, and inﬂammatory gene ex-
pression levels were analyzed.




sn-glycero-3-phosphocholine (DPPC) and 1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (Rho-PE)
were obtained from Avanti Polar Lipids (Alabaster AL, USA). Cholesterol
(Chol) and N-succinimidyl-S-acetylthioacetate (SATA) were purchased
from Sigma-Aldrich (St. Louis MO, USA).
Rapamycin (Sirolimus) was purchased from LC laboratories. 4′,6-
Diamidino-2-phenylindole (DAPI) was obtained from Roche (Woerden,
The Netherlands) and paraformaldehyde from Fluka (Zwijndrecht, The
Netherlands). All chemicals used were of analytical grade unless
otherwise stated.
2.2. Preparation of liposomes
Liposomes were prepared from a mixture of DPPC, Cholesterol and
Mal-PEG2000-DSPE in the respective molar ratio of 65: 25: 10 which
equals to respective amounts of 43, 9 and 27 mg in 3 ml of chloroform:
methanol (9:1, v/v) to a ﬁnal concentration of 30 mM total lipid (TL).
Fluorescently labeled liposomes were prepared by adding Rhodamine-
PE to the lipid mixture at 0.2 mol% of total lipid. Rapamycin was dis-
solved with the lipid mixture at a concentration of 20 nmol/μmol TL,
which is equivalent to 1.7 mg rapamycin. Organic solvents were re-
moved using a rotary evaporator and subsequent drying under a ni-
trogen ﬂow. The resulting drug-lipid ﬁlm was hydrated by adding 3 ml
of HBS buﬀer pH 7.4 (10 mM Hepes containing 135 mM NaCl), fol-
lowed by sonication in an ice-bath using a tip sonicator (Bandelin
Sonopuls) for 10 min and incubation for 1 h at room temperature.
Unilamellar liposomes were prepared by multiple extrusion steps using
a Lipex™ Extruder (Northern Lipids, Burnaby, BC, Canada) over poly-
carbonate membranes (Nuclepore, Pleasanton, CA, USA) at diﬀerent
pore size range (from 0.4 μm to 0.1 μm). PEGylated Liposomes (i.e.
prepared with PEG2000-DSPE instead of Mal-PEG2000-DSPE and
without further E-Selectin addition, see below) are referred to as non-
targeted or control liposomes. For preparation of targeted liposomes,
liposomes were decorated with mouse anti-human E-selectin antibody
H18/7 (IgG2a). The H18/7 antibody was produced in-house by hy-
bridoma cell culture kindly provided by Dr. M. Gimbrone Jr. (Harvard
Fig. 1. Conceptof targeted delivery of rapamycin to TNF-α activated (i.e. inﬂamed) endothelial cells. Immunoliposomes decorated with anti-E-selectin antibodies (1) interact with
E-selectin adhesion molecules expressed on the cell surface of TNF-α activated endothelial cells (2). Receptor-mediated uptake and intracellular delivery/cytosolic release of rapamycin
molecules (3) eventually lead to inhibition of mTOR pathway (4). Adapted with permission from ref (Martini et al., 2012). Copyright 2012, Pearson education Inc.
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Medical School, Boston, MA) and puriﬁed by protein-G aﬃnity chro-
matography (protein G Sepharose fast ﬂow) and dialysis against PBS as
described previously (Everts et al., 2003). H18/7 was modiﬁed with S-
acetylthioacetyl (SATA) (8:1 SATA:Ab mol:mol ratio). SATA-modiﬁed
anti-human E-selectin antibody (2 mg/ml in HBS buﬀer) was treated
with hydroxylamine 0.5 M for 45 min to deprotect the thioacetyl groups
and subsequently reacted to the maleimidyl groups on the liposomes at
15 μg/μmol TL as described before (Everts et al., 2003). Non-reacted
antibody and non-encapsulated rapamycin were removed by passing
liposomes over a PD10 desalting column (GE Healthcare Life Sciences™)
followed by ultraﬁltration using Vivaspin centrifugal concentrators
(Sartorius AG, Aubagne, France) with a molecular weight cut-oﬀ
membrane of 300-kDa.
2.3. Characterization of liposomes
Liposome sizes and polydispersities were measured using dynamic
light scattering (DLS) on an ALV CGS-3 system (Malvern Instruments,
Malvern, UK). Zeta-(ζ) potential of liposomes was measured using a
Malvern Zetasizer Nano-Z (Malvern Instruments, Malvern, UK) with
universal ZEN 1002 dip cells and DTS (Nano) software. Rapamycin
content of the liposomes was determined in 100 μl aliquots which were
disrupted by diluting in 300 μl of acetonitrile. Rapamycin content was
determined by high performance liquid chromatography on a Waters
Acquity HPLC system (Waters Corporation, Milford, MA, USA)
equipped with a Sunﬁre C18 column (5 μm bead size; 4.6 × 150 mm)
thermostated at 60 °C and a UV detector operated at 290 nm. The iso-
cratic mobile phase (1 ml/min) was composed of 70% acetonitrile and
30% water. For each sample batch, six calibration points were always
prepared using serial dilutions of rapamycin in acetonitrile in the
concentration range: 200, 160, 120, 80, 40nmol/ml and blanc matrix).
Calibration samples with a concentration of 40 nmol/ml (i.e. lowest
concentration in the calibration) could be easily measured on the HPLC
system, achieving good signal to noise ratios (S/N> >10). The total
lipid concentration was determined according to Rouser et al. (Rouser
et al., 1970). Conjugation of Ab to the surface of liposomes was con-
ﬁrmed with dot blot assay, using HRP conjugated Goat-anti-Mouse IgG
(H + L) Secondary Antibody (Thermo Fischer Scientiﬁc). Liposomes
were further characterized by determining the concentration of surface
coupled Ab, using mouse IgG (Sigma Aldrich) as a standard via Micro-
BCA assay (Pierce Biotechnology, Rockford, IL, USA).
The number of antibody molecules coupled per liposome (p) was
calculated by geometric arguments according to formula (1) below, as
described previously by Adrian and co-workers (Adrian et al., 2007).
p = π/6 × CAb × (3dbl × R2–3R × dbl2 + dbl3) × Mab−1 × VLs−1
(1)
In which (CAb) is measured concentration of antibody (gram per mol
of lipid), (R) is the average diameter (nanometers) of the spherical li-
posomes, (VLs) and (dbl) represent speciﬁc lipid volume and lipid bi-
layer thickness, respectively, and (MAb) is the molecular mass of the
antibody.
2.4. Cell lines and culture conditions
Human umbilical vein endothelial cells (HUVEC) were obtained
from Lonza (Breda, The Netherlands). Cells were grown in endothelial
cell growth medium-2 (EGM-2) (Lonza, Breda, The Netherlands), con-
sisting of endothelial basal medium-2 (EBM-2) supplemented with
growth factors and antibiotics (EGM-2 SingleQuots kit, Lonza). The
cells were kept in culture at 37 °C in a humidiﬁed atmosphere con-
taining 5% CO2/95% air. Experiments were performed with cells of
passage 3–7.
2.5. Binding and uptake of ﬂuorescent labeled liposomes
Binding of liposomes was studied by incubating TNF-α activated
endothelial cells with rhodamine-labeled liposomes at 4 °C. HUVEC
were seeded at 8000 cells/well in 6-well chamber slides (Lab-Tek®
supplier). After 24 h, the cells were activated with TNF-α (recombinant
human tumor necrosis factor-α; Boehringer, Mannheim, Germany), at
concentration of 10 ng/ml for 4 h at 37 °C and subsequently incubated
with rhodamine labeled liposomes at 4 °C (0.5 mM TL; 1 h at 4 °C). Cells
were washed with PBS and ﬁxed with 4% paraformaldehyde in PBS.
Nuclei were stained with DAPI (1 μg/ml; 5 min at room temperature)
and washed again with PBS. Slides were mounted on glass cover slide
using ﬂuorSave (Calbiochem, San Diego, CA, USA) and analyzed for
binding of labeled liposomes with a Keyence microscope (BZ-9000
BioRevo, Keyence®).
Uptake of Rhodamine labeled liposomes by TNF-α activated en-
dothelial cells was determined by ﬂow cytometry. HUVEC were added
at concentration of 10,000 cells/well in U-bottom shaped 96-well plates
(Becton & Dickinson, Mountain View, CA, USA), activated with TNF-α
(10 ng/ml; 4 h at 37 °C) and subsequent incubated with rhodamine
labeled liposomes in a concentration range of 0.02–3 μM TL in EGM-2
cell culture medium for 3 h at 37 °C in the dark. After removal of cul-
ture medium and excess of liposomes the cells were washed three times
with cold PBS containing 0.3% BSA. Cells were collected by cen-
trifugation for 5 min at 500g at 20 °C and washed with an acidic buﬀer
(200 mM glycine containing 150 mM NaCl, pH 3.0) to remove cell
surface bound liposomes. Next, cells were ﬁxed with 10% formalin
solution. Uptake of Rhodamine labeled liposomes by the cells was
quantiﬁed via ﬂow cytometry with BD FACSCanto (Becton
& Dickinson). Per sample 10,000 events were collected and the samples
were prepared in triplicate. Data were analyzed with BD FACSDiva™
software (Becton & Dickinson) and expressed as mean ﬂuorescence in-
tensity.
2.6. Eﬀects of rapamycin-loaded liposomes on cultured cells
2.6.1. Eﬀect of rapamycin on cell viability
The cell viability upon incubation with rapamycin at diﬀerent
concentrations was evaluated via MTS assay, which measures the mi-
tochondrial (metabolic) activity of the cells. HUVEC were seeded into
96-well plates: 8000 cells were seeded per well. After 24 h of seeding
the medium was refreshed with fresh medium containing TNF-α
(10 ng/ml), and 50 μl of rapamycin dilutions in medium prepared from
a stock solution of rapamycin in DMSO was added to the cells, corre-
sponding to a ﬁnal concentration of 2.5–50 μM. After 48 h of incuba-
tion, MTS assay (Promega, Leiden, The Netherlands) was performed
according to manufacturer’s protocol.
2.6.2. Eﬀect of rapamycin liposomes on migration of endothelial cells
HUVEC were seeded in 6 well plates at a density of 80,000 cells per
well. After overnight adherence of the cells to the well plates in full
EGM-2 medium, cells were activated with TNF-α (10 ng/ml; 4 h at
37 °C), followed by treatment with either free rapamycin or diﬀerent
liposomal formulations equivalent to 10 μM rapamycin. After 12 h, a
scratch wound was made in the cell monolayer with a p20 pipet tip.
Cells and dimensions of the scratch wound were imaged and recorded
at 20 x magniﬁcation with a Nikon TE2000 microscope. Cells were
washed once with PBS and incubated for an additional 16 h with fresh
medium before imaging of the scratch wound areas. Scratch wound
surface area was analyzed using NIH ImageJ software, and expressed
relative to the initial scratch wound area.
2.6.3. Eﬀect of rapamycin liposomes on proliferation of endothelial cells
The eﬀect of rapamycin and liposomes containing rapamycin on
endothelial cell proliferation was analyzed in two diﬀerent
S. Gholizadeh et al. International Journal of Pharmaceutics 548 (2018) 759–770
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experimental setups, using either short-term exposure followed by a
recovery period or long-term continuous exposure. In detail, HUVEC
were seeded at a density of 5000 cells/well in 96-well plates. After
overnight adherence to the plates, cells were activated with TNF-α as
described above (10 ng/ml for 4 h at 37 °C) after which the medium
was replaced by fresh culture medium containing either free rapamycin
or liposomal rapamycin in a concentration range of 25 nM − 40 μM.
For short term exposure, the medium was refreshed with drug-free
medium after 4 h followed by an additional 44 h incubation period,
while long-term exposure involved one continuous 48 h period of in-
cubation with drug-containing medium. Next, culture media were re-
placed by drug-free medium containing BrdU reagent (Roche Applied
Science, Penzberg, Germany), after which cells were cultured for an
extra 24 h (in total 72 h). Cell proliferation was assayed by BrdU-col-
orimetric immunoassay according to the supplier’s protocol. A standard
curve was created in order to convert sample optical density (OD) va-
lues into proliferating cell numbers per well. Sequential dilutions of
cells were prepared from a stock solution to obtain a calibration curve
for the response of various concentrations of cells (781, 1563, 3125,
6250 and 125000 cells per well), as a double linear plot of absorbance
values (OD) against proliferating cell number. Cells were seeded and
cultured for 24 h. Cells were incubated with BrdU reagent for an extra
24 h and incorporation of BrdU was detected with a BrdU cell pro-
liferation ELISA kit. The total number of cells required to construct the
curve in triplicate was 2.4 × 106, which is a quantity that can be har-
vested from a 70% conﬂuent T175 ﬂask (175 cm2).
2.6.4. Eﬀect of rapamycin liposomes on mRNA expression and intracellular
signaling
The eﬀect of rapamycin liposomes on inﬂammatory signaling was
investigated by Q-PCR mRNA expression analysis. HUVEC were seeded
in 12 well plates at 50,000 cells per well and allowed to adhere over-
night before activation with TNF-α for 4 h at 37 °C, followed by in-
cubation for 24 h at 37 °C with medium containing either 10 μM ra-
pamycin or its equivalent in liposomal rapamycin. RNA was isolated
using RNeasy® Mini Plus Kits (Qiagen, Venlo, the Netherlands) ac-
cording to the manufacturer’s protocol. The concentration of RNA was
determined by both NanoDrop® ND-1000 spectrophotometer
(Wilmington, DE) and by agarose (1%) gel electrophoresis.
Complementary DNA (cDNA) to respective RNA samples was generated
by a 20 μl mixture containing SuperScript™ III RNaseH-Reverse
Transcriptase (Invitrogen, supplied by Life Technologies, Bleiswijk, the
Netherlands), RNaseOut inhibitor (40 U) (Invitrogen) and 250 ng
random hexamers (Promega, Leiden, the Netherlands). cDNA solutions
were diluted to 10 ng/ml with MilliQ, and 1 μl was used for each PCR
reaction.
Human GAPDH (Hs99999905_m1), E-selectin (Hs00174057_m1), VCAM-
1(Hs00365486_m1), VEGF-A (Hs00173626_m1), hTIE2 (Hs00176096_m1),
TGF-b (Hs00171257_m1) and mTOR (Hs01042424_m1) primer probes were
purchased as Assay-on-Demand from Applied Biosystems (Nieuwerkerk a/d
IJssel, the Netherlands). These primer probes together with Absolute QPCR
Rox Mix (Thermo Fischer Scientiﬁc) were used for real-time PCR analysis
performed on an ABI PRISM 7900HT Sequence Detector (Applied
Biosystems). The mean of obtained threshold cycle values (Ct) were analyzed
by the comparative Ct method. The respective genes were normalized to
human GAPDH, resulting in ΔCt values. Average ΔCt values of non-activated
cells were deducted from the values of the TNF-α activated cells and the
relative mRNA levels were calculated by 2−ΔCt for the respective genes.
Experiments were performed in duplicate with two independently prepared
formulations (each time samples were analyzed in duplo).
Eﬀects of rapamycin on signaling events downstream from mTOR
were also investigated by anti-phospho-Western blotting. For phospho-
Western blotting, HUVEC were seeded at 100,000 cells per well in 6-
well plates and allowed to adhere overnight before activation with TNF-
α for 4 h at 37 °C and incubation with free rapamycin or liposomal
rapamycin formulations at concentration of 10 μM rapamycin for
another 4 h at 37 °C. Finally, cells were stimulated by addition of 0.5%
insulin for 10 min. Insulin is a known stimulator of the mTOR signaling
cascade and activation of the insulin receptor results in phosphorylation
of both mTOR (at Ser 2448) and S6-ribosomal protein (at Ser 235/236)
kinases (Pellegatta et al., 2006). After washing with cold PBS, the cells
were lysed in radioimmuneprecipitation assay (RIPA) buﬀer, con-
taining phosphatase/kinase inhibitor cocktail (Thermo Fischer Scien-
tiﬁc), (120 μl/well), on ice for 30 min and centrifuged at 14,000g at
4 °C for 15 min. The obtained supernatants were stored at−20 °C until
further evaluation. The protein concentration of the samples was de-
termined by micro-BCA assay. Aliquots corresponding to 15 μg of the
protein cell lysate were subjected to SDS-PAGE on 4–12% gradient
NuPAGE Novex Bis-Tris mini-gels and electro-transferred onto ni-
trocellulose membranes via an iBlot Dry Blotting system. Membranes
were blocked with 5% BSA in Tris-buﬀered saline containing 0.1%
Tween-20 (TBS-T) for 2 h at room temperature, followed by staining
overnight at 4 °C for phospho-mTOR (Ser 2448) and phospho-S6 ribo-
somal protein (Ser235/236) using rabbit polyclonal antibodies (Cell
Signaling Technology, Inc.). β-Actin (Cell Signaling Technology, Inc.)
was stained as control. Antibodies were diluted 1:1000 in 5% BSA in
TBS-T according to the manufacturer’s protocol. After three times
washing with TBS-T, membranes were incubated for 1 h at room tem-
perature with goat anti-rabbit peroxidase-conjugated secondary anti-
body diluted 1:1000 in 5% BSA in TBS-T. Proteins were detected using
supersignal west femto chemiluminescent substrate (Thermo Fischer
Scientiﬁc) and visualized using a Gel Doc imaging system equipped
with a XRS camera and Quantity one analysis software (Bio-Rad, Her-
cules, CA, USA). Densitometric analysis was done using NIH Image J
software. Phosphorylation intensity of mTOR and S6 protein of cells
exposed to diﬀerent formulations were normalized versus insulin acti-
vated control cells. Experiments were performed in duplicate with two
independently prepared formulations.
2.7. Statistical analysis
For the cell-based (in vitro) experiments, statistical analysis of the
data was performed using Graphpad Prism software (Graphpad soft-
ware 5.0, San Diego CA, USA), using analysis of variance (ANOVA).
Values for the experiments are represented ± SEM, unless stated
otherwise. Diﬀerences were considered to be signiﬁcant at values of
P < 0.05.
3. Results and discussions
3.1. Preparation and characterization of rapamycin-loaded
immunoliposomes
PEGylated (immuno)-liposomes loaded with rapamycin were pre-
pared by lipid ﬁlm hydration and extrusion. Mouse monoclonal anti-
human-E-selectin antibodies were conjugated to the maleimidyl-PEG-
DSPE anchor after the extrusion steps. The physicochemical properties
of the diﬀerent types of liposomes are given in Table 1. The average
liposome size deﬁned by DLS method was 125 nm with a polydispersity
index of 0.1. It has been reported that under certain conditions micelles
could be an unwanted byproduct in the formulation of liposomes with
high-PEG content (Johnsson and Edwards, 2003). In this work the vo-
lume-weighted Gaussian distribution (not shown) derived from the DLS
analysis showed no micelle formation under the liposomal preparation
conditions applied in this work (Weissig et al., 1998).
The prepared liposomes showed a negative zeta-potential of
−15 mV, most likely due to the localized negative charges on the
phospholipid head groups within the liposomal bilayer (Garbuzenko
et al., 2005).
Based on HPLC analysis of destructed liposomes, rapamycin en-
capsulation eﬃciency of the liposomes was determined to be approxi-
mately 80%, resulting in a formulation with a rapamycin concentration
S. Gholizadeh et al. International Journal of Pharmaceutics 548 (2018) 759–770
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of 0.45 mg/ml. Dot blot analysis of the liposomes clearly showed the
presence of antibody on the surface of targeted liposomes (Fig. 2). From
the micro BCA assay the coupling eﬃciency of the anti-E-selectin to the
liposomes was determined to be 77 ± 3% (SD, n = 2), corresponding
to 13.4 ± 0.14 (SD, n = 2) μg of anti E-selectin Ab per μmol of total
lipid. Combining formula (1) given in Section 2.3 with the literature
values for speciﬁc lipid volume (VLs) of 1.25 nm3and liposome bilayer
thickness (dbl) of 3.7 nm (Enoch and Strittmatter, 1979), plus the mo-
lecular weight of anti E-selectin Ab (approximately 150 kDa), results in
a calculated average of 5.6 Ab molecules coupled per liposome (i.e. 6
Ab molecules/liposome). However, intercalation of the loaded hydro-
phobic drug compound (i.e. rapamycin) into the hydrocarbon chain
region in the lipid bilayer could lead to variations in bilayer thickness,
due to changes in the molecular conformation of the intercalated (drug)
compound (Sun et al., 2008). This eﬀect has previously been reported
to result in a 10% increase in liposome bilayer thickness (dbl) of DPPC
domains loaded with the drug Atorvastatin (Redondo-Morata et al.,
2016). Recalculation of the antibody density assumuing a similar in-
crease in liposome bilayer thikness (i.e. 10% increase in dbl) yielded an
average of 5.9 Ab molecules/liposome.
3.2. Cellular handling of E-selectin targeted liposomes by activated
endothelial cells
The ability of anti-E-selectin targeted liposomes in binding and
uptake by TNF-α activated endothelial cells was studied by ﬂuorescence
microscopy and ﬂow cytometry measurements, respectively. The in-
teraction of immunoliposomes with activated HUVEC was visualized by
means of ﬂuorescence microscopy (Fig. 3). Anti-E-selectin im-
munoliposomes were eﬀectively internalized by the activated
endothelial cells, while control liposomes showed signiﬁcantly less in-
ternalization (Fig. 4).
3.3. Pharmacological activity of rapamycin-loaded liposomes
3.3.1. Cell viability assessment
TNF-α activated HUVEC treated with diﬀerent concentrations of
rapamycin for 48 h did not show reduced viability at concentrations of
rapamycin up to 25 μM. A sharp decrease in cell viability was found at a
rapamycin concentration of 50 μM (Fig. 5). Combining this data with
results from previous studies (Salas-Prato et al., 1996; Yang et al.,
2015), 10 μM rapamycin was chosen as a non-toxic concentration at
which anti-inﬂammatory and other pharmacological eﬀects of targeted
liposomal rapamycin formulations can be evaluated.
3.3.2. Eﬀects of rapamycin liposomes in scratch wound assay
The mTOR signaling cascade controls a wide range of cellular re-
sponses, including cell migration (Berven and Crouch, 2004). To in-
vestigate the pharmacological activity of rapamycin-loaded liposomal
formulations the
migration of endothelial cells was studied in a scratch wound assay.
Semi-quantitative analysis of the scratch wound area revealed that TNF-
α treated endothelial cells (control) repopulated the cell-free area for
more than 90% in 16 h. Treatment with free rapamycin reduced the
closure of the scratch area to 50% in 16 h (supplemental material Fig.
S1 and Fig. 6). Non-targeted liposomes showed a slight 20 reduction of
the scratch wound area closure compared to the control, which was
most likely caused by unspeciﬁc uptake of the liposomes by the cells
within the set exposure time. Importantly, E-selectin targeted liposomes
loaded with rapamycin showed signiﬁcantly enhanced inhibition of cell
migration, with a reduction of up to 60% compared to untreated en-
dothelial cells. One way to explain the mechanisms behind the inhibi-
tion of cell migration and cell motility induced by cytokines such as
TNF-α
is that inhibition of mTOR also blocks the action of vascular en-
dothelial cell growth factor A (VEGF), which is a critical regulator of
angiogenesis and endothelial cell migration through both inhibition of
VEGF synthesis and its signal transduction (Guba et al., 2002; Del
Bufalo et al., 2006). Another way to explain the phenomena is that
rapamycin has an inhibitory eﬀect on mTORc1 by preventing the in-
teraction of mTOR with the raptor protein scaﬀold (Arsham and
Neufeld, 2006).
Table 1
Physicochemical properties of liposomal formulations used in this study.









120 ± 9 0.07 ± 0.03 −12.6 ± 3.2 85 ± 2 n/ae n/a n/a n/a
Control liposomes (rapamycin loaded) 122 ± 2 0.05 ± 0.02 −11.1 ± 5.0 88 ± 3 0.44 ± 0.01 1.85 ± 0.01 80 ± 3 n/a
Rhodamine-labeled control liposomes
(non-loaded)
125 ± 4 0.09 ± 0.08 −17.3 ± 2.0 90 ± 3 n/a n/a n/a n/a
E-selectin targeted loaded liposomes
(rapamycin loaded)
134 ± 5 0.13 ± 0.06 −14.1 ± 6.2 86 ± 4 0.45 ± 0.01 1.96 ± 0.04 82 ± 1 6f
Rhodamine-labeled E-selectin targeted liposomes
(non-loaded)
138 ± 2 0.15 ± 0.07 −15.1 ± 0.9 89 ± 1 n/a n/a n/a 6
Data are presented as mean values ± SD of 2–3 preparations.
*Z-average.
a Polydispersity index.
b Drug/TL mole% determined after liposomal disruption. (The initial Drug/TL mole% prior to liposomal formulation was calculated to be 2).
c Encapsulation eﬃciency = (rapamycin-loaded in lipid bilayer)/(rapamycin added).
d Number of attached antibody molecules per liposome.
e Not applicable.
f The lipid bilayer thickness is corrected for loaded rapamycin, see main text for details.
Fig. 2. Dot blot analysis of anti-E-selectin coupling to liposomes. Liposomal stock solu-
tions at indicated dilution ranges were subjected to anti-mouse-IgG immunodetection
which demonstrated conjugation of anti-E-selectin mouse-monoclonal antibody to the
immunoliposomes..
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3.3.3. Eﬀects of rapamycin formulations on proliferation of activated
endothelial cells
Both endothelial migration and proliferation can contribute to clo-
sure of the scratch wounds, as discussed in the previous paragraph.
Although we studied the scratch wound healing at incubation times
shorter than the doubling time of HUVEC (approximately 48 h) over-
night repopulation of the scratch wound area cannot be fully attributed
to endothelial cell migration only. We therefore studied the potential
inhibitory eﬀects on endothelial cell proliferation in two diﬀerent
setups, using either prolonged exposure for a period of 48 h or short-
term exposure for 4 h followed by a 44 h recovery (i.e. treatment-free)
period. The latter experimental conditions mimic in vivo drug exposure,
in which drug peak levels are alternated with drug-free periods. To
investigate the correlation between absorption value (BrdU incorpora-
tion) and number of proliferating cells, a calibration curve was made
out of serial dilutions of HUVEC per well. In this way, the absolute
absorbance values obtained for control cells and each of the treatments
could be converted to the number of proliferating cells per well
(Fig. 7A). In the short term exposure study (Fig. 7B) neither free ra-
pamycin, nor the control loaded liposomal formulation of rapamycin
signiﬁcantly aﬀected endothelial cell proliferation in the studied dose
range. Only the highest concentration of E-selectin targeted rapamycin-
loaded liposomes (25 μM) showed slight reduction (∼10%) in en-
dothelial cell proliferation from average 5722 cells/well (control) down
Fig. 3. Wide-ﬁeld ﬂuorescence microscopy pictures of TNF-α activated HUVEC incubated (4 h) with rhodamine labeled liposomes. (A): rhodamine labeled E-selectin targeted liposomes;
(B): rhodamine labeled control liposomes. Objective lens magniﬁcation of 20×. Rhodamine is depicted as red, DAPI (nuclear staining) as blue. Scale bars in the ﬁgures represent 50 μm.
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. Internalization of E-selectin targeted liposomes by activated endothelial cells. Mean Fluorescence Intensity (MFI) of cells incubated with rhodamine labeled E-selectin targeted
liposomes (■) and rhodamine labeled control liposomes (▲) after 3 h incubation at 37 °C. Cells were treated with an acid wash (pH: 3.0) after incubations to remove surface bound
liposomes. Data are presented as mean ± SEM of three experiments using the same formulation.
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to 5081 (cells/well). After long-term exposure of 48 h (Fig. 7C), both
free rapamycin and E-selectin targeted liposomes loaded with rapa-
mycin inhibited endothelial cell proliferation, while control loaded li-
posomes showed less anti- proliferative activity. The contribution of E-
selectin directed uptake of rapamycin-loaded liposomes was most pro-
minently observed at 1 and 5 μM concentrations, which highlights the
added value of targeted liposomes for intracellular delivery of rapa-
mycin. At high concentrations of rapamycin (25 μM), passive uptake of
free rapamycin and receptor-mediated uptake of rapamycin-loaded
immunoliposomes resulted in similar eﬀects of the delivered drug
within the target cells, which can be attributed to saturation of the E-
selectin uptake pathway and to overall saturation of the mTOR in-
hibition by rapamycin under those conditions. Lastly, control liposomes
did not show any eﬀect on cell proliferation in the short-term assay and
only showed activity after continuous exposure, which can be explained
by the presence of some non-speciﬁc uptake of the liposomes upon
continuous incubation.
The results obtained from this experiment correlate well with the
previously discussed inhibiting eﬀect of rapamycin on cell migration
and motility. It can be concluded that within the 16 h time frame at
concentration of 10 μM, the rapamycin inhibiting eﬀect on the re-
population of the scratch wound area is not entirely due to its eﬀect on
cell motility and migration, but can also be attributed to its anti-
proliferative eﬀect.
3.3.4. Eﬀects of rapamycin liposomes on gene expression
Real-time q-PCR analysis was used to examine whether rapamycin
and its liposomal formulations aﬀect mRNA expression of proteins re-
lated to inﬂammation under TNF-α activated and/or non-activated
conditions (Fig. 8). In total 6 genes were studied, including: in-
ﬂammation induced adhesion molecules (VCAM-1 and E-selectin); an-
giogenesis mediators (TIE2 receptor and VEGF); ﬁbrosis cytokine (TGF-
α) and mTOR itself. First, the eﬀect of TNF-α on the gene expression of
the selected genes was evaluated. The activated cells showed a strong
( > 100 fold) increase in gene expression of both VCAM-1 and E-se-
lectin (Fig. 8A and B). Expression of adhesion molecules, especially E-
selectin, plays a main role in this study as speciﬁc binding of the im-
munoliposomes to E-selectin mediates liposome uptake. The cell
binding assays discussed in Section 3.2 (see also Fig. 3) showed that E-
selectin expression is already elevated at t = 4 h (i.e. the time point for
adding the liposomal formulations to the cells). The results on the gene
expression of adhesion molecules indicate that their expression is en-
hanced in presence of TNF-α even at t = 24 h. In general, these ﬁndings
are consistent with previous studies in which it was shown that ex-
posure to TNF-α either after 4 or 24 h induces the expression of E-se-
lectin and VCAM-1 mainly via activation of NF-αB pathway (Wagener
et al., 1997; Rahman et al., 1998).
Upon activation of the cells with TNF-α, a 4.4 and 5.6 fold increase
in gene expression of angiogenesis mediators was observed, compared
to resting cells, for the TIE2 angiopoietin receptor and the VEGF ligand
respectively (Fig. 8C and D). However, the precise role of TNF-α in
angiogenesis has been a subject of debate in scientiﬁc literature
(Sainson et al., 2008). Several in vitro studies have shown that TNF-α
can be either proangiogenic or antiangiogenic, depending mainly on
cell environmental factors (Sainson et al., 2008). With the experimental
conditions used in this work, we demonstrated that TNF-α induced gene
expression of both the TIE2 receptor and the VEGF ligand. These
ﬁndings are in good agreement with previous studies that also reported
that TNF-α induced these above mentioned gene expressions (TIE2 and
VEGF), both of which are reported to be mediated through the NF-αB
pathway (DeBusk et al., 2003; Chen et al., 2004; Nagineni et al., 2012;
Yuan et al., 2012).
TGF-α is a pleiotropic cytokine which has either inﬂammatory or
anti-inﬂammatory activities, depending on the cellular environment. In
this study, we could not detect changes in TGF-α gene expression upon
cell activation with TNF-α (Fig. 8E). Using diﬀerent cell types, a study
by Chen and coworkers reported that TNF-α expression induced TGF-α
secretion in macrophages and vice versa (Chen et al., 2008), while
another study by Sullivan and coworkers demonstrated that TNF-α
plays signiﬁcant role in regulating TGF-α in lung ﬁbroblasts through
AP-1 activation in vitro (Sullivan et al., 2009). However, under the
experimental conditions we could not detect any change in TGF-α gene
expression between the cells activated with TNF-α and the non-acti-
vated resting cells.
Fig. 5. MTS cell viability assay on TNF-α activated HUVEC. Cells were exposed to solu-
tions containing diﬀerent concentrations of rapamycin for 48 h. Data are normalized
compared to control (non-treated) cells. Results are presented as mean ± SEM of three
experiments.
Fig. 6. Eﬀect of rapamycin-loaded liposomes on migration of TNF-α activated endothelial
cells. Repopulation of endothelial cells in a scratch wound was investigated with TNF-α
activated HUVEC that had been pre-incubated with rapamycin formulations at 10 μM for
12 h. Data have been expressed as semi-quantitative analysis of closure of the scratch
wound area, as calculated from the images taken at t = 0 h and t = 16 h (see supple-
mental material for images). Data are plotted as mean values ± SEM of three experi-
ments with the same formulations; **p< 0.01, ***p<0.001 compared to free rapamycin
and control.
S. Gholizadeh et al. International Journal of Pharmaceutics 548 (2018) 759–770
765
The results obtained in this work show an approximately 2-fold
increase in mTOR gene expression for the TNF-α activated cells com-
pared to the resting cells (Fig. 8F). This is consistent with previous
studies which showed that TNF-α up-regulates mTOR gene expression
by activation of the NF-αB pathway (Dan et al., 2008; Karonitsch et al.,
2015).
When introduced to TNF-α activated cells, both free rapamycin and
immunoliposomes loaded with rapamycin signiﬁcantly reduced the
gene expressions of VCAM-1, E-selectin, VEGF and TIE2, as shown in
Fig. 8A–D. However, no eﬀect was detected for mTOR and TGF-α gene
expressions (Fig. 8E, F). Control (i.e. non-targeted) liposomes loaded
with rapamycin showed less eﬀect on the overall gene expression as
compared to their (targeted) counterparts. Taken together, the data
suggest that the liposomal formulation that allows for targeted rapa-
mycin delivery into inﬂammation activated endothelial cells, mediates
on average 50% downregulation of the target genes (i.e. VCAM-1, E-
selectin, VEGF and TIE2) compared to TNF-α activated (control +)
cells. Free rapamycin also caused a signiﬁcant
Fig. 7. Cell proliferation was determined in
TNF-α activated HUVEC by BrdU-incorpora-
tion after 48 h of total incubation period. (A):
Eﬀect of proliferating cell number on absor-
bance at 450 nm, measured using BrdU in-
corporation assay. (B): Cells were exposed for
4 h to rapamycin formulations followed by
recovery period of 44 h in fresh medium. (C):
Cells were exposed for 48 h to rapamycin
formulations continuously. Data are plotted
as mean values ± SEM of three experiments
with the same formulations; *p < 0.05,
***p < 0.001 compared to free rapa treat-
ment.
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decrease in the expression of these same genes compared to TNF-α
activated (control +) cells, which conﬁrms that the drug itself is re-
sponsible for inducing the reported eﬀects in HUVEC. Encapsulation of
rapamycin in liposomes is intended to improve selectivity versus a
speciﬁc cell type (in present study: inﬂammation activated en-
dothelium), thus avoiding other cell types. Hence, the comparison be-
tween targeted liposomes and control liposomes loaded with rapamycin
better reﬂects the improvement obtained by targeted delivery via E-
selectin. Our results demonstrate that the ﬁnal formulation retains its
eﬃcacy (at equal levels to free rapamycin) while we also demonstrate
the importance of E-selectin mediated active uptake which is speciﬁc
for endothelial cells. Targeted liposomes were (at least) 15% more ef-
fective in inhibiting gene expression than free rapamycin. When com-
paring their impact on the expression of E-selectin (Fig. 8B), the dif-
ference between targeted liposomes loaded with rapamycin and free
rapamycin is even more pronounced. Similar results regarding the ef-
fectiveness of the targeted liposomes are also observed in cell migration
and proliferation assays. Most likely, the active delivery of rapamycin
by the targeted liposomes resulted in the highest intracellular con-
centrations within the designated time period.
3.3.5. Eﬀects of rapamycin liposomes on mTOR signaling cascade
To induce E-selectin over-expression on the surface of the HUVEC,
the cells were ﬁrst exposed to TNF-α for 4 h. As shown previously, this
step is essential for active binding and uptake of E-selectin targeted
liposomes, while TNF-α is also one of the inﬂammatory cytokines that
aﬀects cell signaling pathways, such as activation of mTOR in HUVEC
(Glantschnig et al., 2001). Insulin is known to strongly modulate
downstream eﬀectors in the mTOR pathway (Pellegatta et al., 2006).
For more details on the eﬀects of insulin on the mTOR pathway, the
reader is referred to the works of Garami et al. and Nave et al. (Garami
et al., 2003; Nave et al., 1999). Therefore, several experiments were
performed to determine whether incubating HUVEC with solely TNF-α
or with a combination of TNF-α and insulin would have an eﬀect on the
phosphorylation of Ser 235/236 of the S6 ribosomal protein and Ser2448
of mTOR. Activation with only TNF-α induced a 72% and 85% increase
in the degree of phosphorylation of mTOR and S6 proteins respectively,
compared to resting cells (control). Exposure of the cells to insulin in
the presence of TNF-α resulted in an increase versus control of 146%
and 120% in phosphorylation of mTOR and S6 proteins respectively
(Fig. 9A–B). While previous studies have reported an increase in
phosphorylation of mTOR and S6 proteins through a PI3kinase-Akt
dependent pathway upon exposure to insulin, such an eﬀect has not yet
been reported in the presence of TNF-α (Scott et al., 1998; Reynolds
et al., 2002; Garami et al., 2003).
Both free rapamycin and E-selectin targeted liposomes loaded with
rapamycin inhibited phosphorylation of mTOR and S6 after a 4 h in-
cubation at a concentration of 10 μM of rapamycin, while control (i.e.
non-targeted) liposomes loaded with rapamycin showed almost no in-
hibitory eﬀect (Fig. 10A and B). These ﬁndings are in good agreement
with our results from the cell migration, proliferation and gene ex-
pression assays, in which E-selectin targeted liposomes loaded with
rapamycin showed a more pronounced inhibiting eﬀect than its non-
targeted counterparts. It should be noted that the conditions in this
experiment diﬀered slightly from the cell migration, proliferation and
gene expression assays described in earlier paragraphs, because insulin
was applied as an additional stimulating factor for the short-lived ac-
tivation of the mTOR pathway upon treatment with rapamycin.
4. Conclusion
Free rapamycin is a potent and eﬃcacious drug in the treatment of
inﬂammatory disorders; its use is however associated with side eﬀects.
The present approach involving its encapsulation in immunoliposomes
Fig. 8. TNF-α activated and non-activated HUVEC were treated with rapamycin and its liposomal formulations for 24 h. (A) VCAM-1, (B) E-selectin, (C) hTIE2, (D) h VEGF-A, (E) TGF-α
(F) mTOR gene expressions determined by q-PCR analyses. Total mRNA input was corrected for the housekeeping gene hGAPDH. Quantitative change in expression was calculated
relative to resting cells (TNF-). Data are plotted as mean values ± SEM of two independent experiments; *p < 0.05, **p < 0.01, ***p < 0.001 compared to TNF-α activated control
cells (TNF + ).
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Fig. 9. Eﬀect of stimulation with TNF-α and com-
bined stimulation with TNF-α and insulin on phos-
phorylation of mTOR (A) and S6 ribosomal protein
(B) in HUVEC. Data are plotted as mean
values ± SEM of two experiments with two sepa-
rately prepared formulations.
Fig. 10. Eﬀect of rapamycin and its liposomal formulations (equivalent to 10 μM rapamycin) on phosphorylation of mTOR (A) and S6 ribosomal protein (lower band) (B) in HUVEC. (1)
represents free rapamycin; (2) control loaded liposomes and (3) E-selectin targeted loaded liposomes. Data are plotted as mean values ± SEM of two experiments with two separately
prepared formulations; ***p < 0.001 compared to control+.
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will provide for a more selective activity of the drug targeted to a
speciﬁc cell type. Anti-E-selectin immunoliposomes were shown to be
attractive nanocarrier systems for targeted delivery of rapamycin to
TNF-α activated endothelial cells. Further studies to evaluate in vivo
eﬃcacy of rapamycin loaded immunoliposomes are necessary to fully
address their value for anti-inﬂammatory therapy.
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